Wadden, PhDand funded by Novo Nordisk, the maker of semaglutidefound that GLP-1 users without known psychopathology werent any more likely to develop depression or suicidal thoughts or actions than controls
Employers took a range of approaches, with some using specialized vendors to provide case management and in other cases, organizing the requirement through the health plan
Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week
CJC1295 has demonstrated the ability to increase fat loss and bolster muscle mass while enabling the body to more efficiently synthesize protein
When Crohn's Disease Makes GLP-1 Therapy Difficult Active Crohn's flares, recent bowel obstruction, or unhealed post-surgical complications represent periods when starting or continuing GLP-1 therapy may be inappropriate
Cellular Signalling Studies Researchers use Retatrutide to investigate receptor activation and signalling pathways within controlled cellular models